Literature DB >> 21149542

Similarities and differences in the expression of drug-metabolizing enzymes between human hepatic cell lines and primary human hepatocytes.

Lei Guo1, Stacey Dial, Leming Shi, William Branham, Jie Liu, Jia-Long Fang, Bridgett Green, Helen Deng, Jim Kaput, Baitang Ning.   

Abstract

In addition to primary human hepatocytes, hepatoma cell lines, and transfected nonhepatoma, hepatic cell lines have been used for pharmacological and toxicological studies. However, a systematic evaluation and a general report of the gene expression spectra of drug-metabolizing enzymes and transporters (DMETs) in these in vitro systems are not currently available. To fill this information gap and to provide references for future studies, we systematically characterized the basal gene expression profiles of 251 drug-metabolizing enzymes in untreated primary human hepatocytes from six donors, four commonly used hepatoma cell lines (HepG2, Huh7, SK-Hep-1, and Hep3B), and one transfected human liver epithelial cell line. A large variation in DMET expression spectra was observed between hepatic cell lines and primary hepatocytes, with the complete absence or much lower abundance of certain DMETs in hepatic cell lines. Furthermore, the basal DMET expression spectra of five hepatic cell lines are summarized, providing references for researchers to choose carefully appropriate in vitro models for their studies of drug metabolism and toxicity, especially for studies with drugs in which toxicities are mediated through the formation of reactive metabolites.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21149542      PMCID: PMC3061558          DOI: 10.1124/dmd.110.035873

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  40 in total

Review 1.  Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies.

Authors:  Nicola J Hewitt; María José Gómez Lechón; J Brian Houston; David Hallifax; Hayley S Brown; Patrick Maurel; J Gerald Kenna; Lena Gustavsson; Christina Lohmann; Christian Skonberg; Andre Guillouzo; Gregor Tuschl; Albert P Li; Edward LeCluyse; Geny M M Groothuis; Jan G Hengstler
Journal:  Drug Metab Rev       Date:  2007       Impact factor: 4.518

Review 2.  New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process.

Authors:  Shiew-Mei Huang; John M Strong; Lei Zhang; Kellie S Reynolds; Srikanth Nallani; Robert Temple; Sophia Abraham; Sayed Al Habet; Raman K Baweja; Gilbert J Burckart; Sang Chung; Philip Colangelo; David Frucht; Martin D Green; Paul Hepp; Elena Karnaukhova; Hon-Sum Ko; Jang-Ik Lee; Patrick J Marroum; Janet M Norden; Wei Qiu; Atiqur Rahman; Solomon Sobel; Toni Stifano; Kenneth Thummel; Xiao-Xiong Wei; Sally Yasuda; Jenny H Zheng; Hong Zhao; Lawrence J Lesko
Journal:  J Clin Pharmacol       Date:  2008-03-31       Impact factor: 3.126

Review 3.  Polymorphism of human cytochrome P450 enzymes and its clinical impact.

Authors:  Shu-Feng Zhou; Jun-Ping Liu; Balram Chowbay
Journal:  Drug Metab Rev       Date:  2009       Impact factor: 4.518

Review 4.  Liver-enriched transcription factors and hepatocyte differentiation.

Authors:  S Cereghini
Journal:  FASEB J       Date:  1996-02       Impact factor: 5.191

Review 5.  Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation.

Authors:  E L LeCluyse
Journal:  Eur J Pharm Sci       Date:  2001-07       Impact factor: 4.384

Review 6.  Genetic basis of drug metabolism.

Authors:  Margaret K Ma; Michael H Woo; Howard L McLeod
Journal:  Am J Health Syst Pharm       Date:  2002-11-01       Impact factor: 2.637

7.  A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues.

Authors:  Steven N Hart; Ye Li; Kaori Nakamoto; Eva-anne Subileau; David Steen; Xiao-bo Zhong
Journal:  Drug Metab Dispos       Date:  2010-03-12       Impact factor: 3.922

8.  Lack of CYP1A1 expression is involved in unresponsiveness of the human hepatoma cell line SK-HEP-1 to dioxin.

Authors:  Kazuhiro Shiizaki; Seiichiroh Ohsako; Toshie Koyama; Ryoichi Nagata; Junzo Yonemoto; Chiharu Tohyama
Journal:  Toxicol Lett       Date:  2005-07-28       Impact factor: 4.372

9.  Simian virus 40 large tumor antigen-immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens.

Authors:  A M Pfeifer; K E Cole; D T Smoot; A Weston; J D Groopman; P G Shields; J M Vignaud; M Juillerat; M M Lipsky; B F Trump
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

10.  Epoxyeicosatrienoic acids and/or their metabolites promote hypoxic response of cells.

Authors:  Sachiko Suzuki; Ami Oguro; Mayuko Osada-Oka; Yoshihiko Funae; Susumu Imaoka
Journal:  J Pharmacol Sci       Date:  2008-09-06       Impact factor: 3.337

View more
  100 in total

1.  Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery.

Authors:  Brian I Carr; Aldo Cavallini; Catia Lippolis; Rosalba D'Alessandro; Caterina Messa; Maria G Refolo; Angela Tafaro
Journal:  J Cell Physiol       Date:  2013-02       Impact factor: 6.384

2.  From the Cover: Three-Dimensional (3D) HepaRG Spheroid Model With Physiologically Relevant Xenobiotic Metabolism Competence and Hepatocyte Functionality for Liver Toxicity Screening.

Authors:  Sreenivasa C Ramaiahgari; Suramya Waidyanatha; Darlene Dixon; Michael J DeVito; Richard S Paules; Stephen S Ferguson
Journal:  Toxicol Sci       Date:  2017-09-01       Impact factor: 4.849

3.  Quantification of common and planar bile acids in tissues and cultured cells.

Authors:  Stephanie J Shiffka; Jace W Jones; Linhao Li; Ann M Farese; Thomas J MacVittie; Hongbing Wang; Peter W Swaan; Maureen A Kane
Journal:  J Lipid Res       Date:  2020-07-22       Impact factor: 5.922

4.  Influence of a three-dimensional, microarray environment on human cell culture in drug screening systems.

Authors:  Luciana Meli; Eric T Jordan; Douglas S Clark; Robert J Linhardt; Jonathan S Dordick
Journal:  Biomaterials       Date:  2012-09-19       Impact factor: 12.479

5.  Tissue specific synthetic ECM hydrogels for 3-D in vitro maintenance of hepatocyte function.

Authors:  Aleksander Skardal; Leona Smith; Shantaram Bharadwaj; Anthony Atala; Shay Soker; Yuanyuan Zhang
Journal:  Biomaterials       Date:  2012-04-02       Impact factor: 12.479

6.  Mitochondrial dysfunction induced by sertraline, an antidepressant agent.

Authors:  Yan Li; Letha Couch; Masahiro Higuchi; Jia-Long Fang; Lei Guo
Journal:  Toxicol Sci       Date:  2012-03-02       Impact factor: 4.849

7.  Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity.

Authors:  Jiekun Xuan; Si Chen; Baitang Ning; William H Tolleson; Lei Guo
Journal:  Chem Biol Interact       Date:  2015-10-22       Impact factor: 5.192

8.  DNA damage-induced apoptosis and mitogen-activated protein kinase pathway contribute to the toxicity of dronedarone in hepatic cells.

Authors:  Si Chen; Zhen Ren; Dianke Yu; Baitang Ning; Lei Guo
Journal:  Environ Mol Mutagen       Date:  2018-02-05       Impact factor: 3.216

9.  Effects of the chloro-s-triazine herbicide terbuthylazine on DNA integrity in human and mouse cells.

Authors:  Davor Želježić; Suzana Žunec; Marija Bjeliš; Vesna Benković; Marin Mladinić; Blanka Lovaković Tariba; Ivan Pavičić; Ana Marija Marjanović Čermak; Vilena Kašuba; Mirta Milić; Alica Pizent; Ana Lucić Vrdoljak; Nevenka Kopjar
Journal:  Environ Sci Pollut Res Int       Date:  2018-05-02       Impact factor: 4.223

10.  Optimization of Canalicular ABC Transporter Function in HuH-7 Cells by Modification of Culture Conditions.

Authors:  Hee Eun Kang; Melina M Malinen; Chitra Saran; Paavo Honkakoski; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2019-08-01       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.